Sortilin is required for toxic action of Aβ oligomers (AβOs): Extracellular AβOs trigger apoptosis, and intraneuronal AβOs impair degradation pathways

Ayumi Takamura, Yota Sato, Daisuke Watabe, Yasuhide Okamoto, Takashi Nakata, Takeshi Kawarabayashi, Salvatore Oddo, Frank M. Laferla, Mikio Shoji, Etsuro Matsubara

Research output: Contribution to journalArticle

19 Citations (Scopus)

Abstract

Aims: We investigated the pathological relevance of the Aβ oligomer (AβO) cascade hypothesis in 3xTg-AD mice. This study was also designed to elucidate the molecular mechanism underlying the toxic action of AβOs. Main methods: To target the extracellular AβOs in vivo, a monoclonal antibody specific for AβOs was developed using a novel method. Monoclonal 72D9 was intravenously administered to aged 3xTg-AD mice bearing the human AD pathology to investigate the relevance of the AβO cascade hypothesis. To further identify the AβO-binding molecule on the cell surface, small interfering RNA (siRNA) for sortilin was transfected into SH-SY5Y cells. The sortilin-dependent molecular mechanism underlying toxic action of AβOs and/or AβO endocytosis was also assessed in cultured cortical neurons forming synapses. Key findings: The 72D9 immunotherapy of aged 3xTg-AD mice revealed that extracellular and intraneuronal AβOs are related, and that intraneuronal AβOs act upstream of tau. We also found that extracellular AβOs first act as a sortilin ligand, and then induce p75 NTF-mediated apoptosis, endocytosis-induced attenuation of autophagy, or accumulation of AβOs in autophagosomes. Significance: Taken together, these findings provide novel lines of evidence that sortilin governs the toxic action of extracellular AβOs, which affects the degradation and/or clearance of either intraneuronal AβOs or tau. Thus, therapeutic intervention targeting extracellular AβOs themselves or for preventing the interaction between intraneuronal AβOs and tau is a promising strategy to be developed for AD treatment.

Original languageEnglish (US)
Pages (from-to)1177-1186
Number of pages10
JournalLife Sciences
Volume91
Issue number23-24
DOIs
StatePublished - Dec 10 2012
Externally publishedYes

Fingerprint

Toxic Actions
Oligomers
Apoptosis
Degradation
Endocytosis
Autophagy
Immunotherapy
Synapses
Small Interfering RNA
Monoclonal Antibodies
Pathology
Ligands
Neurons
sortilin
Therapeutics
Bearings (structural)

Keywords

  • Aβ immunotherapy
  • Aβ oligomers
  • Alzheimer's disease
  • Intraneuronal Aβ
  • p75NTR
  • Sortilin
  • Tau

ASJC Scopus subject areas

  • Pharmacology, Toxicology and Pharmaceutics(all)
  • Biochemistry, Genetics and Molecular Biology(all)

Cite this

Sortilin is required for toxic action of Aβ oligomers (AβOs) : Extracellular AβOs trigger apoptosis, and intraneuronal AβOs impair degradation pathways. / Takamura, Ayumi; Sato, Yota; Watabe, Daisuke; Okamoto, Yasuhide; Nakata, Takashi; Kawarabayashi, Takeshi; Oddo, Salvatore; Laferla, Frank M.; Shoji, Mikio; Matsubara, Etsuro.

In: Life Sciences, Vol. 91, No. 23-24, 10.12.2012, p. 1177-1186.

Research output: Contribution to journalArticle

Takamura, A, Sato, Y, Watabe, D, Okamoto, Y, Nakata, T, Kawarabayashi, T, Oddo, S, Laferla, FM, Shoji, M & Matsubara, E 2012, 'Sortilin is required for toxic action of Aβ oligomers (AβOs): Extracellular AβOs trigger apoptosis, and intraneuronal AβOs impair degradation pathways', Life Sciences, vol. 91, no. 23-24, pp. 1177-1186. https://doi.org/10.1016/j.lfs.2012.04.038
Takamura, Ayumi ; Sato, Yota ; Watabe, Daisuke ; Okamoto, Yasuhide ; Nakata, Takashi ; Kawarabayashi, Takeshi ; Oddo, Salvatore ; Laferla, Frank M. ; Shoji, Mikio ; Matsubara, Etsuro. / Sortilin is required for toxic action of Aβ oligomers (AβOs) : Extracellular AβOs trigger apoptosis, and intraneuronal AβOs impair degradation pathways. In: Life Sciences. 2012 ; Vol. 91, No. 23-24. pp. 1177-1186.
@article{85adfce6d5f24a4da422c6c24765f5a5,
title = "Sortilin is required for toxic action of Aβ oligomers (AβOs): Extracellular AβOs trigger apoptosis, and intraneuronal AβOs impair degradation pathways",
abstract = "Aims: We investigated the pathological relevance of the Aβ oligomer (AβO) cascade hypothesis in 3xTg-AD mice. This study was also designed to elucidate the molecular mechanism underlying the toxic action of AβOs. Main methods: To target the extracellular AβOs in vivo, a monoclonal antibody specific for AβOs was developed using a novel method. Monoclonal 72D9 was intravenously administered to aged 3xTg-AD mice bearing the human AD pathology to investigate the relevance of the AβO cascade hypothesis. To further identify the AβO-binding molecule on the cell surface, small interfering RNA (siRNA) for sortilin was transfected into SH-SY5Y cells. The sortilin-dependent molecular mechanism underlying toxic action of AβOs and/or AβO endocytosis was also assessed in cultured cortical neurons forming synapses. Key findings: The 72D9 immunotherapy of aged 3xTg-AD mice revealed that extracellular and intraneuronal AβOs are related, and that intraneuronal AβOs act upstream of tau. We also found that extracellular AβOs first act as a sortilin ligand, and then induce p75 NTF-mediated apoptosis, endocytosis-induced attenuation of autophagy, or accumulation of AβOs in autophagosomes. Significance: Taken together, these findings provide novel lines of evidence that sortilin governs the toxic action of extracellular AβOs, which affects the degradation and/or clearance of either intraneuronal AβOs or tau. Thus, therapeutic intervention targeting extracellular AβOs themselves or for preventing the interaction between intraneuronal AβOs and tau is a promising strategy to be developed for AD treatment.",
keywords = "Aβ immunotherapy, Aβ oligomers, Alzheimer's disease, Intraneuronal Aβ, p75NTR, Sortilin, Tau",
author = "Ayumi Takamura and Yota Sato and Daisuke Watabe and Yasuhide Okamoto and Takashi Nakata and Takeshi Kawarabayashi and Salvatore Oddo and Laferla, {Frank M.} and Mikio Shoji and Etsuro Matsubara",
year = "2012",
month = "12",
day = "10",
doi = "10.1016/j.lfs.2012.04.038",
language = "English (US)",
volume = "91",
pages = "1177--1186",
journal = "Life Sciences",
issn = "0024-3205",
publisher = "Elsevier Inc.",
number = "23-24",

}

TY - JOUR

T1 - Sortilin is required for toxic action of Aβ oligomers (AβOs)

T2 - Extracellular AβOs trigger apoptosis, and intraneuronal AβOs impair degradation pathways

AU - Takamura, Ayumi

AU - Sato, Yota

AU - Watabe, Daisuke

AU - Okamoto, Yasuhide

AU - Nakata, Takashi

AU - Kawarabayashi, Takeshi

AU - Oddo, Salvatore

AU - Laferla, Frank M.

AU - Shoji, Mikio

AU - Matsubara, Etsuro

PY - 2012/12/10

Y1 - 2012/12/10

N2 - Aims: We investigated the pathological relevance of the Aβ oligomer (AβO) cascade hypothesis in 3xTg-AD mice. This study was also designed to elucidate the molecular mechanism underlying the toxic action of AβOs. Main methods: To target the extracellular AβOs in vivo, a monoclonal antibody specific for AβOs was developed using a novel method. Monoclonal 72D9 was intravenously administered to aged 3xTg-AD mice bearing the human AD pathology to investigate the relevance of the AβO cascade hypothesis. To further identify the AβO-binding molecule on the cell surface, small interfering RNA (siRNA) for sortilin was transfected into SH-SY5Y cells. The sortilin-dependent molecular mechanism underlying toxic action of AβOs and/or AβO endocytosis was also assessed in cultured cortical neurons forming synapses. Key findings: The 72D9 immunotherapy of aged 3xTg-AD mice revealed that extracellular and intraneuronal AβOs are related, and that intraneuronal AβOs act upstream of tau. We also found that extracellular AβOs first act as a sortilin ligand, and then induce p75 NTF-mediated apoptosis, endocytosis-induced attenuation of autophagy, or accumulation of AβOs in autophagosomes. Significance: Taken together, these findings provide novel lines of evidence that sortilin governs the toxic action of extracellular AβOs, which affects the degradation and/or clearance of either intraneuronal AβOs or tau. Thus, therapeutic intervention targeting extracellular AβOs themselves or for preventing the interaction between intraneuronal AβOs and tau is a promising strategy to be developed for AD treatment.

AB - Aims: We investigated the pathological relevance of the Aβ oligomer (AβO) cascade hypothesis in 3xTg-AD mice. This study was also designed to elucidate the molecular mechanism underlying the toxic action of AβOs. Main methods: To target the extracellular AβOs in vivo, a monoclonal antibody specific for AβOs was developed using a novel method. Monoclonal 72D9 was intravenously administered to aged 3xTg-AD mice bearing the human AD pathology to investigate the relevance of the AβO cascade hypothesis. To further identify the AβO-binding molecule on the cell surface, small interfering RNA (siRNA) for sortilin was transfected into SH-SY5Y cells. The sortilin-dependent molecular mechanism underlying toxic action of AβOs and/or AβO endocytosis was also assessed in cultured cortical neurons forming synapses. Key findings: The 72D9 immunotherapy of aged 3xTg-AD mice revealed that extracellular and intraneuronal AβOs are related, and that intraneuronal AβOs act upstream of tau. We also found that extracellular AβOs first act as a sortilin ligand, and then induce p75 NTF-mediated apoptosis, endocytosis-induced attenuation of autophagy, or accumulation of AβOs in autophagosomes. Significance: Taken together, these findings provide novel lines of evidence that sortilin governs the toxic action of extracellular AβOs, which affects the degradation and/or clearance of either intraneuronal AβOs or tau. Thus, therapeutic intervention targeting extracellular AβOs themselves or for preventing the interaction between intraneuronal AβOs and tau is a promising strategy to be developed for AD treatment.

KW - Aβ immunotherapy

KW - Aβ oligomers

KW - Alzheimer's disease

KW - Intraneuronal Aβ

KW - p75NTR

KW - Sortilin

KW - Tau

UR - http://www.scopus.com/inward/record.url?scp=84869508475&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84869508475&partnerID=8YFLogxK

U2 - 10.1016/j.lfs.2012.04.038

DO - 10.1016/j.lfs.2012.04.038

M3 - Article

C2 - 22579764

AN - SCOPUS:84869508475

VL - 91

SP - 1177

EP - 1186

JO - Life Sciences

JF - Life Sciences

SN - 0024-3205

IS - 23-24

ER -